The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
At under 1100p for one of the best performing stocks over past 10 years, I would suggest this is incredibly cheap and they have market share, pricing power and growth once the storm settles. Sp has dropped over 50% on a review, nothing material and as many in the business know costs are huge, medicines not cheap and economy of scale means the way forward for this type of service with larger organsiations with clear pricing and availability of services. From a competition point of view no small business can or will want to compete as UK regualtion and taxes no longer support the small business, and the route to market even for larger organisations is not easy. CVSG are ideally placed for strong rebound in sp over coming weeks / months.
Here you go - Under Article 19(11) of the UK Market Abuse Regulation (UK MAR), the period of 30 calendar days before the announcement of an interim financial report or a year-end report that an issuer is obliged to make public according to the rules of the trading venue where the issuer's shares are admitted to trading or the law of the United Kingdom, during which a person discharging managerial responsibilities of an issuer is prohibited from conducting any transactions on its own account or for the account of a third party, directly or indirectly, relating to the shares or debt instruments of the issuer or to derivatives or other financial instruments linked to them
It is often a decent signal as there are few people who like to lose money, so with a 30 day restriction on purcahses for bod memebers before any news is released to market it would not be unreasonable to expect something positive in the April trading update.............. David Latin, Non-Executive Chairman, purchased 20,462 ordinary shares at an aggregate price of 180.04p (£37k) following the CFO's 19000 share purchase earlier today (£34k), following David Latin (Chairman ) recent purchase of 117,255 shares @ 183.7p (£215k) & Mitch Flegg's purchase of 75000 at 189p (£141k).
Yup, broker algo's will be set tp collect a few stops today as some will lose their shares in early market crash, share price 1900p this time last year and all wiped off on a lengthy review process that will discover running a business in the UK is thwart with regulation cost,enployer costs, energy costs, product costs, and more costs. A small business is not easy to run and therefore larger business will be more cost effective, hence the growth of CVSG .
Indeed, my point was they launched the start in September 2023 and are still in the process, government depts work at vastly slower pace than any business that needs to generate income, profits etc.
The review started in September 2023 has concluded they need to do a review from March 2024 to April 2024 ! You can't make it up.
Sarah Cardell, Chief Executive of the CMA, said: We launched our review of the veterinary sector last September because this is a critical market for the UK’s 16 million pet owners, We have provisionally decided to launch a market investigation because that’s the quickest route to enable us to take direct action, if needed. The CMA has launched a 4-week consultation to seek views from the sector on the proposal to launch a market investigation. The consultation closes on 11 April 2023 at which point it will consider the responses
The review started in September 2023 has concluded they need to do a review from March 2024 to April 2024 ! You can't make it up.
Sarah Cardell, Chief Executive of the CMA, said: We launched our review of the veterinary sector last September because this is a critical market for the UK’s 16 million pet owners, We have provisionally decided to launch a market investigation because that’s the quickest route to enable us to take direct action, if needed. The CMA has launched a 4-week consultation to seek views from the sector on the proposal to launch a market investigation. The consultation closes on 11 April 2023 at which point it will consider the responses
''the shipowner Henry transporting the crude oil that the company Novum buys from the operator of Lot 95, requested support from PetroTal to control a hydrocarbon spill in the river, which occurred after the cobbling of two of its boats, approximately two kilometers from our operation (puinahua district . Loreto)
Immediately, PetroTal - in support of the Henry company convoy - activated his Contingencies Plan by which properly trained and equipped brigades reached the point of the incident and managed to control the leak of the hydrocarbon.
The event occurred outside the PetroTal control area.
The transport company Henry, owner of the sinister barges and contractor of Novum, has pledged to provide the necessary support to the affected communities''
Reiterating a Bloomberg view of the Pet market growth expected over next few years.
The pet industry is poised to swell from $320 billion today to almost $500 billion by 2030, growth is driven by an increase in spending on pet-related healthcare — including veterinary care, diagnostics, and pharmaceuticals — that has created longer pet lifespans that require more expensive elderly care.
Alongside this longer pet lifespan comes a larger investment in increasingly complex drugs like monoclonal antibodies, which could make the pet pharmaceutical market top $25 billion by 2030. The analysis predicts that increased animal longevity and healthcare improvements might accelerate the use of preventive-care diagnostics as well, with the potential to become a $30 billion global market. Europe represents that largest growth opportunity with a total addressable market around $12 billion with just 8% penetration.
“We’re seeing a profound increase in consumer spending on pets and expect to see this continue through 2030. Consumers are willing to pay more for items for their pets, with the pet food market having the potential to grow more than 50% from current levels by the end of the decade.”
The pet industry is poised to swell from $320 billion today to almost $500 billion by 2030, growth is driven by an increase in spending on pet-related healthcare — including veterinary care, diagnostics, and pharmaceuticals — that has created longer pet lifespans that require more expensive elderly care.
Alongside this longer pet lifespan comes a larger investment in increasingly complex drugs like monoclonal antibodies, which could make the pet pharmaceutical market top $25 billion by 2030. The analysis predicts that increased animal longevity and healthcare improvements might accelerate the use of preventive-care diagnostics as well, with the potential to become a $30 billion global market. Europe represents that largest growth opportunity with a total addressable market around $12 billion with just 8% penetration.
“We’re seeing a profound increase in consumer spending on pets and expect to see this continue through 2030. Consumers are willing to pay more for items for their pets, with the pet food market having the potential to grow more than 50% from current levels by the end of the decade.”
Sp remains out of sync with cash generation and production......initial target 16p+
https://twitter.com/surprised_trade/status/1766009707594953000
A special divi and standard quarterly div of approx 4.5p per share very is likely to be attractive to many with an ex divi date of 25/04/24 and the following divi expected just 4 weeks later (23/05/24) with potential transformational news due anytime in the next few weeks/months anyone trying short term trades will need fabulous luck or knowledge.
David Latin, Non-Executive Chairman, purchased 20,462 ordinary shares at an aggregate price of 180.04p (£37k) following the CFO's 19000 share purchase earlier today (£34k), following David Latin (Chairman ) recent purchase of 117,255 shares @ 183.7p (£215k) & Mitch Flegg's purcase of 75000 at 189p (£141k)....The BOD are buying.
https://twitter.com/surprised_trade/status/1765801930217902485
Tax breaks a great incentive for investment and production....
Broker note with'' a number of catalysts noted that offer upside between 32% & 90%+ (excluding the very likely transformational MPNU deal from it's forward valuation) and a current divi around 7%
We calculate NAV at 169p at a 15% discount rate rising to 244p at a 10% discount rate, offering 32%-91% upside (excluding MPNU or conversion to PIA terms that offer further upside)''
https://twitter.com/surprised_trade/status/1757355886517891140
The Acquisition will transform Harbour into one of the world's largest and most geographically diverse independent oil and gas companies, significant progress has been made on the various approvals and workstreams required for completion, expect the Acquisition to complete in Q4 2024. dividend per share growth for the full year 2023 of c.9%
https://twitter.com/surprised_trade/status/1765647013348004129
Pending a new CEO taking over and surely a non UK Oil/Gas play upcoming with their buying power.
https://twitter.com/surprised_trade/status/1765310431701164313
Added to holding 139p.... cash at bank $450m (2022: $404m), Revenue $1,061.3 million up 12%, Production averaged 47,758 boepd, up 8%, special dividend of US 2.4p, in addition to Q4 23 declared dividend of 2.4p, confident will acquire transformational Exxon Mobil's (MPNU)
https://twitter.com/surprised_trade/status/1765000718711160836
Https://twitter.com/surprised_trade/status/1764299743264399582